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Dry mouth is common in elderly patients. However, the use of saliva substitute has been limited due to
its inedibility. This study investigated the efﬁcacy of oral moisturizing jelly (OMJ), a novel edible saliva
substitute. A pre-post design was conducted in 118 elderly patients diagnosed with hypertension and/or
diabetes mellitus. After using OMJ, signs and symptoms of dry mouth were compared with baseline data.
The properties of saliva were compared between the OMJ use and non-use periods. The use of OMJ for 2
weeks signiﬁcantly reduced symptoms of dry mouth, while the use for 1 month reduced the signs of
xerostomia, prevented the decline of salivary pH(s) and improved buffering capacities. OMJ was equally
effective in patients taking 1 to 2 and 3 to 7 medications. Furthermore, 65% of patients preferred OMJ
over a commercial product. OMJ could be new edible saliva substitute for elderly patients suffering from
dry mouth.
Clinicaltrials.gov ID: NCT02317172.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Xerostomia (dry mouth) is a common complaint of almost 50%
of elderly population.1 Although salivation decreases with age, the
actual causes of xerostomia in elders are likely drug-inducedbol received personal fees for
tion Foundation under Royal
ootham obtained oral mois-
ental Innovation Foundation
ne.
idol University, 999 Phuttha-
Pathom 73170, Thailand.
rachootham).
Inc. This is an open access article uhyposalivation, head and neck irradiation and systemic condi-
tions, such as Sjögren’s syndrome and type 2 diabetes mellitus.2
Many types of medicine cause dry mouth as a side effect e.g.
anti-hypertensive drugs, anti-diabetic drugs, psychotherapeutic
drugs and anti-histamines.3 Owing to the multiple functions of
saliva, hyposalivation leads to speech problems, taste disorders,
chewing and swallowing difﬁculties, ill-ﬁtting dentures and
consequently poor qualities of life.4,5 Furthermore, hyposalivation
results in decreased oral clearance, declined salivary pH and
buffering capacity, and reduced immune defenses.6 These symp-
toms may increase risks of developing infectious oral diseases such
as cervical caries, periodontitis and oral candidiasis.6 Current in-
terventions for xerostomia include systemic therapies such as
cholinergic agonists; topical interventions such as salivander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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terventions such as acupuncture and electrostimulation.7e9 Recent
evidence-based reviews concluded that systemic salivary stimu-
lants e.g. pilocarpine and cevimeline are recommended only for
primary and secondary Sjögren’s syndrome.7 No topical therapies
have strong evidence to support their efﬁcacies.8 Evidences for
acupuncture or electrostimulation devices are insufﬁcient.9 Thus,
the development of novel effective approaches for alleviating
xerostomia is essential.
In recent years, saliva substitutes have gained much attention.
Saliva substitutes are available in various formulations e.g. loz-
enges, sprays, mouth rinses, gels, oils, chewing gums or tooth-
pastes. However, no single product could adequately reproduce the
properties of the natural saliva.10 This is likely due to the inedibility
of those saliva substitutes. The saliva substitute products usually
contain preservatives. Therefore, their uses are limited only to oral
cavity and they are not recommended to be swallowed.10 This
constraint has become critical and thus limited the uses of
commercially available saliva substitutes. Saliva swallowing is a
normal reﬂex to maintain a proper clearance by eliminating gram-
negative bacilli from oropharynx.11 In fact, oropharyngeal infection
and sputum accumulation in patients with xerostomia could in-
crease the risk of aspiration pneumonia.11 Furthermore, saliva
swallowing is critical for food ingestion since the ﬂow of saliva
through oropharyngeal isthmus stimulates swallowing process and
taste perception in oropharyngeal area.12 Therefore, the general
properties of ideal saliva substitutes should be inexpensive, edible,
hydrating, easy-to-swallow but retainable in the mouth.
Recently, oral moisturizing jelly (OMJ) was successfully devel-
oped by joint collaborators from various disciplines including
dentistry, nursing, medicine and food sciences. OMJ is a ready-to-
eat gel with semi-solid appearance but could be melted under
oral environment temperature.13 Upon biting or spooning, the gel
will release some water due to syneresis.14 Since patients with
xerostomia often have chewing and swallowing problems,4 the
texture and gel strength of OMJ were designed based on a previous
research and development of Nutri-jelly,15 a nutritious edible gel
proven to be effective in improving quality of life in head and neck
cancer patients with chewing and swallowing difﬁculties.16 Unlike
Nutri-jelly, OMJ has no nutrients but contains buffering agents and
high water content. In addition, OMJ has neutral pH (6.8e7) and
normal buffering capacity, imitating the natural saliva.13 The most
severe xerostomia was found in head and neck cancer patients
undergoing radiation therapy. A home-use-test of OMJ was con-
ducted in 36 cancer patients with xerostomia.13 The patients used
the OMJ products for two weeks and recorded their uses and sat-
isfactions in their diaries. The study showed that 82.3% of the
cancer patients were satisﬁed with the texture, ﬂavor and moisture
of OMJ.13 In addition, the satisfaction of OMJwas higher than that of
a commercially available saliva gel.13 After taking one spoon of OMJ,
most patients required an additional spoon after 2 h and 45 min,
suggesting that OMJ can retain in the mouth for almost 3 h.13
Although dry mouth is common in elderly population, the inter-
vention studies for treatment of dry mouth in these patients have
been limited.17 Therefore, the aim of this study was to investigate
the efﬁcacy of OMJ in elderly patients.
Methods
Intervention
Oral moisturizing jelly (OMJ) products were provided by Dental
Innovation Foundation under Royal Patronage, a non-proﬁt orga-
nization. The OMJ products passed food safety test (free of patho-
genic micro-organisms and hazardous metals), according to theregulation of Thai Food and Drug Administration (FDA). The OMJ
products were manufactured in a clean room by hot-ﬁlling. The
OMJ products have 6-month shelf life at room temperature. Be-
sides, the products are available in two ﬂavors: strawberry and lime
mint (Fig. 1a), and their biochemical properties are not different.13
The products are semi-solid with consistency comparable to Na-
tional Dysphagic Diet (NDD) level 1,18 non-nutritive, water-
releasing and ready-to-eat by spoon (Fig. 1b).
Participants
Patients were recruited from the out-patient departments of
two hospitals located in Lampang province of Thailand. Prior to the
recruitment, all patients were screened based on the following
inclusion criteria: being diagnosed with hypertension or diabetes
mellitus and receiving medical therapies for at least 1 year; having
complaint of xerostomia. Exclusion criteria were as follows: having
subjective dry mouth score <3 or objective dry mouth score <2;
having oral candidiasis; being unable to make reliable decisions or
communications. All patients signed their written informed con-
sents prior to data collection. Their identities had been protected,
following Good Clinical Practice guidelines of International Con-
ference on Harmonisation (ICH-GCP).
Sample size calculation
Sample size was identiﬁed by priori power analysis using G
Power 3.1.19 The effect size was calculated from the pilot data of 10
patients using their mean subjective dry mouth scores and stan-
dard deviations at baseline, 2 weeks and 1 month after OMJ use.
Based on repeated measure analysis of variance (repeated measure
ANOVA), it was necessary to enroll 70 patients to achieve 90% po-
wer at 2-sided 1% signiﬁcance level. To account for an up to 30%
drop-out rate, at least 100 patients were required. Initially, 126
patients agreed to be enrolled in the study. Finally, completed data
were presented from 118 patients (93.6%).
Study procedures
This study was approved by the institutional ethic committee
for research in human of Department of Health, Ministry of Health,
Thailand, and performed according to Declaration of Helsinki. To
investigate the possible beneﬁts of OMJ, a pre-post design was
used. At the beginning, all patients who passed the inclusion
criteria signed their written informed consents. Then, all of them
received their favorite ﬂavored OMJ products in a volume of 50 ml
(10 ml  5 times) per day. After using the OMJ for 2 weeks and 1
month, their signs and symptoms of xerostomia were measured as
objective and subjective dry mouth scores, respectively, and
compared with their baseline data (prior to use). Their properties
of saliva, including salivary pH(s), buffering capacities and ﬂow
rates, were subsequently compared with their baseline data. Since,
the patients were also taking other medicines with potential side
effects on saliva qualities during the study period, their changes of
saliva properties during ‘OMJ use period’ were monitored and
compared within the same patients during ‘OMJ non-use’ period.
The data for ‘OMJ non-use’ period were collected within the same
patients three months later. To ensure that the baseline data of
“OMJ use and non-use” periods was comparable, the history of
medication uses was rechecked. It was conﬁrmed that all patients
received similar medications and doses in both periods.
Measures
The primary outcomemeasures were satisfaction and subjective
dry mouth scores. The secondary outcomes measures were
Fig. 1. Oral moisturizing jelly (OMJ). (a) The packages of OMJ in hot-ﬁlled pyramidal boxes: strawberry ﬂavored (red labeled) and lime mint ﬂavored (green labeled) products. (b)
The consistency of OMJ is comparable to NDD level 1 with pudding-like texture, no-need-to-chew and easy-to-pour-out properties (Top image). Upon cut or bitten, the gel will
release water (Middle image). OMJ can be taken by spoon, like regular food (bottom image). (c) The pie chart demonstrates the percentages of patients who selected either OMJ (red
area) or a commercial saliva gel (blue area) as their favorite choices. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this
article.)
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ﬂow rates.
Satisfaction
At the beginning, all patients had few spoons of OMJ and a
commercially available artiﬁcial saliva gel, in a random order. Then,
they were asked to choose their favorite gel (either OMJ or the
commercial one). At the end of the ‘OMJ use’ period, the patients
were asked to rate their appreciation for OMJ in a scale of 0e10.
Subjective dry mouth score
The patients were interviewed for their symptoms of xero-
stomia including dry mouth, dry throat, chewing and swallowing
difﬁculties, taste disturbances, speech problems, night-time water
intakes and ill-ﬁtting dentures.20 The patients were advised to give
the scores on the severity of symptoms in a scale ranging from
0 (not troublesome) to 10 (most troublesome).20 The subjective drymouth scores of each patient were calculated as the mean of all
item scores. Patients with a score less than 3 were excluded from
data analysis.
Objective dry mouth score
The patients were examined for their signs of dry mouth
including loss of pooled saliva, mouth mirror stickiness, stringy or
foamy appearance, labial dehydration and irresponsiveness to pa-
rotid stimulation.21 Objective dry mouth scores were calculated as
the number of observed dry mouth signs (0e5). Patients with a
score less than 2 were excluded.
The properties of saliva
The various parameters of saliva including salivary pH(s),
buffering capacities and ﬂow rates were measured in all patients
during OMJ use and non-use periods. As depicted in Fig. 2, the
salivary pH(s), buffering capacities and ﬂow rates were measured
Fig. 2. The measurement of saliva qualities in OMJ use and OMJ non-use periods. This
diagram shows time points where salivary pH(s), buffering capacities and ﬂow rates
were measured. The OMJ use period started three months after the OMJ non-use
period ended.
Table 1
Descriptive characteristic of the study samples.
Characteristic N % Mean  sd. Range
Age 71.22  6.8 58e88
Gender
Female 84 71.19
Male 34 28.81
Systemic condition
Only Hypertension (HT) 73 61.86
Both HT and DM 28 23.73
Only Diabetes Mellitus (DM) 13 11.02
Other e.g. gout, seizure 4 3.39
With dyslipidemia
Yes 51 43.22
No 67 56.78
Medication(s)
Single druga 21 17.80
Combination of two drugsb 28 23.73
Combination of three drugsb 32 27.12
Combination of four drugsb 18 15.25
Combination of ﬁve to seven drugsb 19 16.10
Smoking
Yes 2 1.69
No 116 98.31
Baseline subjective dry mouth score (0e10) 5.15  1.57 3.0e9.2
Baseline objective dry mouth score (0e5) 3.42  1.01 2.0e5.0
Baseline stimulated salivary ﬂow rate (ml/min) 0.216  0.118 0.1e0.6
Baseline salivary pH 6.15  0.34 5.6e6.6
Baseline salivary buffering capacity 5.75  1.95 2.0e9.0
Oral lesions associated with xerostomia
Cervical caries 65 55.08
Coated tongue 56 47.46
Petechiae 18 15.25
Fissured tongue 13 11.02
Depapillated tongue 6 5.08
Daily water drink (servings/day) 7.36  2.73 4.0e15.0
a Included calcium channel blocker (Amlodipine), Beta-adrenergic blocker
(Atenolol), Angiotensin converting enzyme inhibitor (Enalapril), Anti-type 2 dia-
betic (Metformin), Thiazide diuretic (HCTZ), Angiotensin II receptor antagonist
(Losartan).
b Combination between: 1) Calcium channel blockers (i.e. Amlodipine) and other
drugs e.g. hypolipidemic (Simvastatin), Anti-type 2 diabetic (Metformin), Anti-
platelet (Aspirin (ASA)), Beta-blocker (Atenolol), Diuretic (HCTZ, Furosemide,
Moduretic), Vitamin (Folic acid), Anti-gout (Allopurinol), Angiotensin Converting
Enzyme Inhibitor (Enalapril), 2) Beta-adrenergic blockers (Atenolol) and other drugs
e.g. anti-type 2 diabetic (Glipizide), thiazide diuretic (HCTZ), 3) Hypolipidemic
(Simvastatin) and others such as anti-type 2 diabetic (Glibenclamide), Angiotensin II
receptor antagonist (Losartan), 4) Diuretic (Furosemide) and Angiotensin converting
enzyme inhibitor (Enalapril), 5) Beta-adrenergic blocker (Metroprolol) and thiazide
diuretic (Tritazide), 6) Insulin injection (Mixtard 30 HM Penﬁll) and Minerals (Cal-
cium carbonate).
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OMJ use period. Then, all subjects were advised to stop their uses
of OMJ for 3 months; thereafter, the measurements were
collected as baseline, and after 2 weeks and 1 month of OMJ non-
use period. For the measurement of saliva’s properties, whole
saliva samples were collected within 10 min after stimulation by
parafﬁn chewing. Stimulated salivary ﬂow rates, pH(s) and
buffering capacities were measured by using commercially
available GC Saliva Check-Buffer kits (GC Asia, Singapore).22 This
method was feasible in dental ofﬁces and was proven to be well-
correlated with laboratory titrations.23 As instructed on the
product sheet, salivary ﬂow rates less than 1 ml/min and salivary
pH(s) < 6.8 were considered abnormal. Salivary buffering ca-
pacities were categorized into very low (score 0e5), low (6e9)
and normal (10) capacities. The buffering capacities of each
patient after using the OMJ for 2 weeks and 1 month were
compared with that of his baseline data. Then, they were repre-
sented by improved, unchanged or worse buffering capacities.
For example, a patient had low buffering capacity at baseline,
very low buffering capacity at 2 weeks and low buffering capacity
at 1 month. The changes of buffering capacity in this patient
would be categorized as worse capacity at 2 weeks and un-
changed capacity at 1 month. The percentages of patients in each
category (improved, unchanged or worse buffering capacities)
were calculated as the number of patients in each category
divided by the number of total patients.
Patients with baseline saliva qualities in a normal range i.e. ﬂow
rate of  1 ml/min, pH  6.8 and buffering capacity score 10 were
excluded from data analysis.
Statistical analysis
The sample size and power were calculated by G Power 3.1.
Data from 118 patients yield a post-hoc power of 0.95 for repeated
measure ANOVA. Graphing and statistical analyses were per-
formed by using Graph Pad Prism 5.0. Descriptive statistics were
used to summarize data as followings: mean of subjective and
objective dry mouth scores, salivary pH(s) from all patients. The
normality of data distributions was veriﬁed by the D’Agostino &
Pearson omnibus test. Parametric statistical tests were used only
when the data passed normality test (p > 0.05). Comparisons of
subjective and objective dry mouth scores between 2 weeks, 1
month and baseline measurements were analyzed by using
repeated measure ANOVA. The Bonferrini tests identiﬁed time
points with signiﬁcance differences from the baseline data. Com-
parisons of changes in salivary pH(s) between OMJ use and non-
use periods were analyzed by using Two-way ANOVA, followed
by Tukey’s multiple comparisons. Comparisons of changes in
salivary buffering capacities between “OMJ use” and “OMJ non-
use” periods or between patients taking 1 to 2 and 3 to 7 medi-
cations were analyzed by chi-square tests. Comparisons of
subjective and objective dry mouth scores, and salivary pH(s) at
different time points between patients taking 1e2 and 3e7
medications were analyzed by Two-way ANOVA. All tests were
performed with two-tailed methods (where possible), a ¼ 0.05. p-
values <0.05 were considered statistically signiﬁcant.Results
Baseline data
Initially, 126 patients agreed to participate in the study. Finally,
completed data were obtained from 118 patients (93.6%). The de-
mographic data and illness characteristics of the patients were
shown in Table 1. Seventy one percent of the patients were female
with average age of 71.2 years. Ninety-eight percent of the patients
were non-smokers. Eighty ﬁve percent of the patients had been
diagnosed as hypertensive (HT) along with or without diabetes
mellitus (DM). Some patients had only DM. Almost ﬁfty percent of
the patients were suffering from dyslipidemia and required hypo-
lipidemic drugs; e.g. Simvastatin. Eighty two percent of the patients
had taken more than one type of drugs consistently. A calcium
channel blocker; i.e. Amlodipine 10 mg and an anti-type 2 diabetic
drug; i.e. Metformin 500 mg were most common drugs used for
treatment of HT and DM, respectively. At baseline, the patients had
signs and symptoms of xerostomia with high average objective and
subjective dry mouth scores, respectively. Furthermore, their saliva
S. Dalodom et al. / Geriatric Nursing 37 (2016) 101e109 105qualities were poor with abnormally low ﬂow rates, acidic pH(s)
and low buffering capacities. Consequently, ﬁfty-ﬁve percent of
them had cavities at the neck of tooth (cervical caries) and forty-
seven percent of them had microbial plaque accumulations on
their tongues (tongue coating). Due to their dry mouth problems,
the patients drank water frequently and their water intakes ranged
from 4 to 15 servings/day.
Satisfaction
As shown in Fig. 1c, sixty-ﬁve percent of the patients selected
OMJ as their favorite gels, while 35% preferred the commercial
artiﬁcial saliva gel. The highest preference of OMJ was correlated
with easily swallowing, extra deliciousness and more hydrating. An
example of quotes from the patients was, “OMJ is my favorite gel
because it can be swallowed similar to natural saliva. Compared to
the other brand, OMJ keeps mouth and throat more moisten.” At the
end of OMJ use period, the patients provided average appreciation
score of 7.98  2.6 (out of 10). Examples of quotes from the patients
were; “After using OMJ, I don’t choke while eating”; “OMJ is veryFig. 3. The effect of OMJ on signs and symptoms of dry mouth and saliva’s properties. (a an
period reﬂected the effect of OMJ on symptoms and signs of dry mouth, respectively. Each
scores. Error bars indicated 95% conﬁdence interval. Repeated measured ANOVA tests showe
scores, compared with baseline data. Bonferrini tests identiﬁed time points with signiﬁcant
pH(s) between OMJ use and OMJ non-use periods. Each bar represented the mean of saliva
Error bars indicated 95% conﬁdence interval. Two-way ANOVA showed a signiﬁcant differenc
differences from baseline. (*) ¼ p < 0.05; (***) ¼ p < 0.001. (d) Comparisons of buffering c
represented the percentage of patients who had improved (blue), unchanged (orange) and w
chi-square test showed a signiﬁcant difference between the two periods (p ¼ 0.035). (For in
web version of this article.)helpful. My mouth and throat are no longer dry”; “Previously,
frequent water sipping was required when swallowing food. With
OMJ, I can freely swallow the food.” Three months later, most pa-
tients complained that their dry mouth symptoms returned after
stopping OMJ and they had simultaneously requested for OMJ. A
great example of quotes from patients was, “Without OMJ, I had dry
and sore throat, and excessive coughingwith sputum. It was difﬁcult
to endure without OMJ and frequent water sipping was required for
swallowing of food. I really would like to have OMJ once more.”
Effect of oral moisturizing jelly on subjective and objective dry
mouth scores
To evaluate the effects of OMJ on symptoms and signs of xero-
stomia, subjective and objective dry mouth scores after using OMJ
were compared with their baseline scores. As shown in Fig. 3a, the
average subjective drymouth scores had 73% and 88% reduction from
their baseline data, after using OMJ for 2 weeks and 1 month,
respectively (p < 0.0001). The results suggested that the repeated
uses of OMJ could signiﬁcantly decrease the symptoms of dry mouth.d b) The changes of subjective (a) and objective (b) dry mouth scores during OMJ use
bar represented the percentage of the respective scores compared with their baseline
d signiﬁcant changes in subjective (p < 0.0001) and objective (p ¼ 0.0086) dry mouth
differences from baseline. (**) ¼ p < 0.01; (***) ¼ p < 0.001. (c) Comparisons of salivary
ry pH(s) at various time points; pink ¼ baseline, orange ¼ 2 weeks, green ¼ 1 month.
e between the periods (p ¼ 0.0015). Tukey’s tests identiﬁed time points with signiﬁcant
apacities in all patients between OMJ use and OMJ non-use periods. Each stacked bar
orse (pink) buffering capacities during 1 month of OMJ use or OMJ non-use periods. The
terpretation of the references to color in this ﬁgure legend, the reader is referred to the
S. Dalodom et al. / Geriatric Nursing 37 (2016) 101e109106Interestingly, as shown in Fig. 3b, there was about 16% reduction of
objective drymouth scores (p< 0.0086), after using OMJ for 1month,
while its 2-week use showed a slight (but not signiﬁcant) decrease of
dry mouth signs. These results suggested that the alleviation of dry
mouth signs required repeated uses of OMJ for at least 1 month.
Effect of oral moisturizing jelly on saliva’s properties
Since all patients were allowed to take their medications for
hypertension/diabetes mellitus during ‘OMJ use’ period, their saliva
properties could be ﬂuctuated. To evaluate the actual effect of OMJ
on saliva’s properties, their changes in salivary pH(s) and buffering
capacities were compared between OMJ use and OMJ non-use pe-
riods within the same patients. As shown in Fig. 3c, the mean sali-
vary pH(s) were decreased in a time-dependent manner and
become signiﬁcantly decreased at 1 month during OMJ non-use
period. In contrast, the average salivary pH(s) were not decreased
during “OMJ use” period. Interestingly, the signiﬁcant increase in
salivary pH(s) toward the normal level was noted after using the
OMJ for 2 weeks. Two-way ANOVA analyses showed that salivary
pH(s) of OMJ use period were signiﬁcantly better than that of OMJ
non-use period (p ¼ 0.0015). Similarly, as shown in Fig. 3d, the
number of patients with worse buffering capacities was decreased
from thirty two percent in OMJ non-use period, to ﬁfteen percent in
OMJ use period. Furthermore, the number of patients with improvedFig. 4. The effect of OMJ on saliva buffering capacity. Comparisons of buffering capacities bet
low (c and d) baseline buffering capacities. (a and b) Each stacked bar represented the pe
buffering capacities, during 2 weeks (a) and 1 month (b) of OMJ use or OMJ non-use periods
(blue) and unchanged (orange) buffering capacities, during 2 weeks (c) and 1 month (d) of OM
(For interpretation of the references to color in this ﬁgure legend, the reader is referred tobuffering capacities was increased from ten percent in OMJ non-use
period, to twenty percent in OMJ use period. Statistical analyses
showed that salivary buffering capacities of OMJ use period were
signiﬁcantly better than that of OMJ non-use period (p ¼ 0.035).
Since the patients were a mixed group of very low- (score 0e5) and
low- (score 6e9) baseline buffering capacities, separate analyses for
each group were performed. As shown in Fig. 4, in the very-low-
baseline group salivary buffering capacities after using OMJ for
both 2weeks and 1monthwere signiﬁcantly better than that of OMJ
non-use period. In contrast, in the low-baseline group the signiﬁ-
cance was found only after using OMJ for 1 month. These results
suggested that the patients with very-low-baseline buffering ca-
pacities were more responsive to OMJ. A slight increase in the sali-
vary ﬂow rates was observed after OMJ use. The average salivary
ﬂow rates after 2 week and 1 month OMJ uses were 0.69  0.53 ml/
min and 0.75 0.57 ml/min, respectively, while that of baseline was
0.63  0.51 ml/min. However, statistical analyses showed that these
differences were not signiﬁcant (p ¼ 0.2782, KrusaleWallis test).
Effect of OMJ in the patients based on the number of their
medications
The patients were stratiﬁed into two groups based on the
number of medications consumed by the patients: (1) taking 3e7
medications (n ¼ 69), (2) taking 1e2 medications (n ¼ 49). Toween OMJ use and OMJ non-use periods in elderly patients, with low (a and b) and very
rcentage of patients who had improved (blue), unchanged (orange) and worse (pink)
. (c and d) Each stacked bar represented the percentage of patients who had improved
J use or OMJ non-use periods. p-value(s) calculated from chi-square tests were shown.
the web version of this article.)
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the efﬁcacy of OMJ, the changes in subjective and objective dry
mouth scores, salivary pH(s) and buffering capacities during ‘OMJ
use’ period were compared between the two groups. As shown in
Fig. 5, OMJ was very effective in both groups. No signiﬁcant dif-
ferences were noted between the two groups after using the OMJ.
The buffering capacities were signiﬁcantly improved in both groups
after using OMJ for 2 weeks, as compared to OMJ non-use period
(Fig. 6a). In addition, the improved buffering capacities were noted
in the 1-2-medication group after using OMJ for 1 month (Fig. 6b
right). While in case of the 3e7-medication group, the buffering
capacities at 1 month were improved but not signiﬁcantly, when
compared to OMJ non-use period (Fig. 6b left). These results sug-
gested that OMJ might be effective regardless of the number of
medications.Fig. 5. Comparisons of OMJ effects between patients taking 3e7 medications (n ¼ 69) and th
and objective (b) dry mouth scores and salivary pH(s) (c) during OMJ use period, between p
Each bar represented the mean of respective scores at various time points. Error bars indicate
two groups in either subjective or objective scores (p ¼ 0.7803, 0.549, 0.3607, respectively). (d
weeks (d) and 1 month (e), between patients taking 3e7 medications and those taking 1e2
had improved (blue), unchanged (orange) and worse (pink) buffering capacities. p-value(s)
color in this ﬁgure legend, the reader is referred to the web version of this article.)Intervention ﬁdelity
To ensure treatment ﬁdelity according to NIH Behavioral Change
Consortium (BCC),24 treatment designs for dose, duration and
outcome measures were reviewed and agreed by a team of six
professional dentists. All patients visited the same hospital for data
collections on the same day. On each visit, the data were collected
by the same team of researchers to ensure the consistency of the
protocol. The assessments of all parameters on each visit were
performed by the same researchers in all patients (one researcher
for each parameter). The same team of researchers collected data of
subjects from the two different hospitals. To enhance the adher-
ence of intervention deliveries, a food sensory testing was per-
formed at the ﬁrst visit. All patients had few spoons of OMJ (both
ﬂavors) and selected their favorite one for further home use.ose taking 1e2 medications (n ¼ 49). (a and c) Comparisons of changes in subjective (a)
atients taking 3e7 medications (red bar) and those taking 1e2 medications (blue bar).
d standard deviations. Two-way ANOVA showed no signiﬁcant differences between the
and e) Comparisons of changes in buffering capacities of patients after using OMJ for 2
medications, as labeled. Each stacked bar represented the percentage of patients who
calculated from chi-square tests were shown. (For interpretation of the references to
Fig. 6. The effect of OMJ on saliva buffering capacities in patients taking 3e7 medications and those taking 1e2 medications. Comparisons of changes in the buffering capacities
between OMJ use and OMJ non-use periods after 2 week (a) and 1 month (b). Each stacked bar represented the percentage of patients who had improved (blue), unchanged
(orange) and worse (pink) buffering capacities, in patients taking 3e7 medications (left) and those taking 1e2 medications (right). p-value(s) calculated from chi-square tests were
shown. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
S. Dalodom et al. / Geriatric Nursing 37 (2016) 101e109108Instructions for using OMJ were carried by a researcher for all pa-
tients to ensure consistent deliveries. The treatment receipts (their
uses of OMJ) were evaluated by patient diaries (daily records) and
patients’ interviews at follow-up visits. The treatment enactment
focused on the degree to which the patients continuously received
OMJ and returned for dental follow-up visits. Among 126 patients
agreed to be enrolled in this study,118 patients (93.6%) returned for
complete follow-up visits and reported continuous daily intake of
50ml (10ml 5 times) of OMJ. However, a very small percentage of
patients did not adhere to protocols and did not return for follow-
up visits.
Discussion
Dry mouth is a critical problem in elderly people with poly
pharmacy. It could increase the risk of oral diseases, taste dys-
functions, chewing and swallowing difﬁculties, speech problems
and poor qualities of life.25,26 Intra-oral topical agents are among
the most commonly recommended treatments for the manage-
ment of xerostomia.27 Currently, no interventions were proven
effective in elderly people diagnosed with systemic diseases.7,8 In
general, xerostomia causes dryness in both oral and oropharyngeal
mucosa(s), and currently available saliva substitutes are
preservative-containing and unsuitable to eat.28 Therefore, they
lack bathing effect to oropharynx and their efﬁcacies are limited.
Recently, “oral moisturizing jelly (OMJ),” a novel edible gel, was
developed to overcome these limitations.13 In this study, a pre-post
design was conducted in 118 older people taking medications for
hypertension and/or diabetes mellitus. Continuous daily uses ofOMJ for 1 month were found to reduce signs and symptoms of dry
mouth and improved the saliva’s qualities of elderly patients.
Furthermore, OMJ was equally effective in patients taking various
medications. This intriguing ﬁndings of this investigation demand
further randomized control studies.
The efﬁcacy of OMJ more likely resulted from its unique physical
and biochemical properties. Unlike other available saliva sub-
stitutes, OMJ is edible, easy-to-swallow and hydrating to mouth
and throat.13 The design of OMJ’s consistency was based on an
insight from research and development of Nutri-jelly, a food gel
suitable for cancer patients with chewing and swallowing difﬁ-
culties.15,16 According to National Dysphagia Diet (NDD) standards
for texture modiﬁed diets,18 the consistencies of Nutri-jelly and
OMJ were likely NDD level 1. Since Nutri-jelly was proved edible by
head and neck cancer patients with swallowing difﬁculties,16 OMJ
might also be suitable for individuals with chewing or swallowing
difﬁculties. Since older people often had chewing and swallowing
difﬁculties due to tooth loss and dry mouth,29 future studies should
address the effects of OMJ on the improvement of dietary intake in
dysphagic older patients.
The moisturizing effect of OMJ more likely resulted from syn-
eresis property; i.e. the release of water from gel upon biting or
spooning,14 which rehydrated the dry mouth.13 This was consistent
with a previous report showing that the gel formulation appeared
to be the most efﬁcient and appreciated by patients among other
oral lubricants.30 In addition, the 3-h mouth retention property of
OMJ likely allowed continuously hydrating and buffering effects, as
shown in other oral care products.31 The use of OMJ for 1 month
signiﬁcantly improved the buffering capacities, when compared to
S. Dalodom et al. / Geriatric Nursing 37 (2016) 101e109 109OMJ non-use period. This ﬁnding suggested an efﬁcacy of OMJ.
However, it is worth noting that the major proportion of the pa-
tients remained unchanged in their buffering capacities after using
OMJ (Figs. 3d and 4). This is more likely due to the lack of bicar-
bonate buffering agents in the OMJ product. Drymouth problems in
the patients of the current study were mainly caused by the side
effects of anti-hypertensive/anti-diabetic drugs on autonomic
nervous systems.32 The autonomic nerves stimulate the release of
parotid saliva containing bicarbonate buffer. These medications
affect the autonomic nervous system and thereby decrease the
release of bicarbonate in the saliva.33 Currently, OMJ contains only
phosphate but not bicarbonate buffer systems. Thus, future
research to improve the efﬁcacy of OMJ should consider including
bicarbonate buffer into this product.
A similar attempt to use a saliva gel in elderly people with
abnormal salivary ﬂow rates and buffering capacities had been
made. Unfortunately, no signiﬁcant results were obtained. For
example, a prophylactic gel effective in adults with normal salivary
secretion failed to alleviate dry mouth in patients with poly-
pharmacy.34 The authors discussed that the problems were caused
by the lack of compliances due to the changeover of personnel/or
the inconvenience of uses during weekend travels.34 In this pre-
post study, the success of intervention likely resulted from the
appreciations and adherences of the patients to the continuous
daily uses of OMJ, evidenced by the high appreciation scores and
the high follow-up returns.
Conclusion
Continuous daily uses of OMJ for 1 month reduced the signs and
symptoms of xerostomia and improved saliva’s properties of the
elderly patients who were taking multiple medications. OMJ is a
new edible salivary substitute with potential clinical applications,
and thus deserving further exploration in a larger populationwith a
randomized-controlled design.
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